{
  "model": "gemini-3.1-pro-preview",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/gemini-3-1-pro-preview-tumor-vaccine-ici-run-1",
  "success": true,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": true,
  "durationMs": 108465,
  "agentCostUsd": 0.15243440000000003,
  "graderCostUsd": 0.014253749999999999,
  "totalCostUsd": 0.16668815000000003,
  "agentUsage": {
    "promptTokens": 17686,
    "cachedTokens": 8152,
    "responseTokens": 2877,
    "thinkingTokens": 8101,
    "totalTokens": 28664
  },
  "graderUsage": {
    "promptTokens": 3849,
    "cachedTokens": 0,
    "responseTokens": 136,
    "thinkingTokens": 401,
    "totalTokens": 4386
  },
  "totalUsage": {
    "promptTokens": 21535,
    "cachedTokens": 8152,
    "responseTokens": 3013,
    "thinkingTokens": 8502,
    "totalTokens": 33050
  },
  "modelVersions": [
    "gemini-3.1-pro-preview"
  ],
  "agentFinalText": "I have completed the task. Here is the checklist of the written output files:\n\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments for combination therapy.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls for various arms.\"\n    },\n    {\n      \"id\": \"human-metastatic\",\n      \"label\": \"Human retrospective cohort\",\n      \"sample_size_or_observations\": \"130\",\n      \"description\": \"Metastatic patients receiving ICI treatment compared by vaccine status.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Results derived from specific models requiring careful translation to broad clinical settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination broadens tumor antigen display.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Effects are based on preclinical metrics and may vary across distinct tumor types.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Prior mRNA vaccination is associated with improved survival in patients receiving ICI.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Retrospective observational design and varied vaccination timing limit definitive causal interpretation.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combination therapy increases immune infiltration into tumors.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Increased infiltration measured in mouse models may not uniformly guarantee clinical response in all human tumors.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"SARS-CoV-2 mRNA Vaccines May Sensitize Tumors to Immune Checkpoint Inhibitors\",\n  \"plain_language_summary\": \"Researchers investigated whether delivering mRNA vaccines directly into tumors could make them more susceptible to immune checkpoint inhibitors (ICIs). In preclinical mouse models, the combination of intratumoral mRNA vaccination and anti-PD-L1 therapy improved tumor control and increased immune cell infiltration. Notably, vaccine-only treatments did not yield durable tumor control in non-immunogenic models, and ICI-only treatments had limited activity without the vaccine. The mRNA vaccine induced an interferon-driven inflammatory state that increased the presentation of tumor proteins on the cell surface, making the tumors more visible to the immune system. A retrospective study of 130 human patients with metastatic cancer showed an association between prior SARS-CoV-2 mRNA vaccination and improved survival under ICI treatment. However, this study underscores that lipid particles without mRNA did not reproduce this sensitization, and blocking the interferon response eliminated the benefits.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination was shown to broaden the antigen display on tumor cells in preclinical models.\",\n    \"The mRNA vaccine induced a strong type I interferon response that increased PD-L1 expression, providing a target for ICIs.\",\n    \"A retrospective analysis observed an association between prior SARS-CoV-2 mRNA vaccination and improved survival in human cancer patients receiving immune checkpoint inhibitors.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study was retrospective and non-randomized, meaning residual confounding is likely and causation cannot be definitively established.\",\n    \"The timing of vaccination relative to ICI initiation varied widely among the human patients, further complicating the analysis.\",\n    \"Lipid particle controls lacking mRNA failed to reproduce the sensitization effect, showing the necessity of the active mRNA component.\",\n    \"Blocking type I interferon signaling eliminated the sensitization benefit, highlighting that the effect relies heavily on this specific pathway.\",\n    \"Mouse model effects may not accurately map to all human tumors, and tumor-type heterogeneity limits direct clinical translation.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune Checkpoint Inhibitors (ICIs)\",\n      \"definition\": \"Drugs that block checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells more effectively.\"\n    },\n    {\n      \"term\": \"MHC-I Peptidome\",\n      \"definition\": \"The complete set of peptides presented by Major Histocompatibility Complex class I molecules on the surface of cells to signal the immune system.\"\n    },\n    {\n      \"term\": \"Type I Interferon\",\n      \"definition\": \"A group of signaling proteins released by host cells in response to the presence of pathogens, typically viruses, to trigger immune responses.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on the surface of some cells that can suppress the immune system by binding to PD-1 on T cells; blocking it can help the immune system fight cancer.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective randomized clinical trials confirm the causal benefits of intratumoral mRNA vaccination combined with ICIs in humans?\",\n    \"How does the timing of mRNA vaccination relative to ICI initiation impact the effectiveness of the combination therapy?\",\n    \"Which specific solid tumor types respond best to this combination therapy approach?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-19T19:48:21.773Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-19T19:48:25.315Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-19T19:48:25.315Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-19T19:48:28.493Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-19T19:48:28.493Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-19T19:48:28.493Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-19T19:48:28.493Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-19T19:49:36.562Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-19T19:49:36.562Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-19T19:49:36.562Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-19T19:49:36.563Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "value": {
      "verdict": "pass",
      "scores": {
        "faithfulness": 5,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [],
      "summary": "Across all JSON files, the outputs accurately reflect the reportâ€™s study design (preclinical mouse + retrospective human cohort), main mechanistic claims (type I IFN-driven antigen presentation changes and PD-L1 upregulation), quantitative findings (all reported percentages/fold-changes/p-value), and key control/conditional results (vehicle/ICI-only limits, lipid particle control null, IFNAR1 blockade eliminating benefit). The human evidence is appropriately framed as retrospective/associational"
    }
  }
}
